Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie oceniające długoterminowe bezpieczeństwo inklakumabu podawanego uczestnikom z niedokrwistością sierpowatokrwinkową

29 października 2026 zaktualizowane przez: Pfizer

Otwarte badanie rozszerzone mające na celu ocenę długoterminowego bezpieczeństwa stosowania inklakumabu podawanego uczestnikom z niedokrwistością sierpowatokrwinkową, którzy brali udział w badaniu klinicznym dotyczącym inklakumabu

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.

All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

241

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Southern
      • Jizan, Southern, Arabia Saudyjska, 82943
        • Prince Mohammed bin Nasser Hospital
      • Rio de Janeiro, Brazylia, 20211-030
        • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
      • São Paulo, Brazylia, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, Brazylia, 01232-010
        • Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
      • São Paulo, Brazylia, 08270-120
        • CEPEC-Centro de Pesquisa Clinica
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazylia, 41253-190
        • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
    • Pernambuco
      • Recife, Pernambuco, Brazylia, 50070-460
        • Multihemo Servicos Medicos S/A
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazylia, 90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • Ribeirão Preto, São Paulo, Brazylia, 14051-140
        • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
      • São José do Rio Preto, São Paulo, Brazylia, 15090-000
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto
      • Eldoret, Kenia, 30100
        • International Cancer Institute
      • Nairobi, Kenia, 00100
        • Gertrude's Children's Hospital
      • Nairobi, Kenia, 00100
        • Kenya Medical Research Institute - Centre for Respiratory Disease Research
      • Nairobi, Kenia, 00200
        • Strathmore University CREATES
    • Siaya County
      • Kisumu, Siaya County, Kenia, 40600
        • KEMRI/CRDR Siaya Clinical Research Annex
    • Atlántico
      • Barranquilla, Atlántico, Kolumbia, 080020
        • Clinica de la Costa Ltda.
    • Cesar Department
      • Valledupar, Cesar Department, Kolumbia, 200001
        • Sociedad de Oncología y hematología del Cesar
    • Beirut
      • Hamra, Beirut, Liban
        • American University of Beirut Medical Center
    • North Lebanon
      • Tripoli, North Lebanon, Liban
        • Nini Hospital
      • Enugu, Nigeria, 460000
        • University of Nigeria Teaching Hospital
      • Kaduna, Nigeria, 800212
        • Barau Dikko Teaching Hospital/Kaduna State University
      • Kano, Nigeria, 700223
        • Aminu Kano Teaching Hospital
      • Lagos, Nigeria, 100254
        • Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
    • Cross River State
      • Calabar, Cross River State, Nigeria, 540242
        • University of Calabar Teaching Hospital
    • Federal Capital Territory
      • Abuja, Federal Capital Territory, Nigeria, 900211
        • National Hospital Abuja
      • Gwagwalada, Federal Capital Territory, Nigeria, 902101
        • University of Abuja Teaching Hospital
    • Kaduna State
      • Zaria, Kaduna State, Nigeria, 810105
        • Ahmadu Bello University Teaching Hospital
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
    • Alabama
      • Mobile, Alabama, Stany Zjednoczone, 36604
        • University of South Alabama Children's and Women's Hospital
      • Mobile, Alabama, Stany Zjednoczone, 36604
        • Strada Patient Care Center, Pediatric Hematology
      • Mobile, Alabama, Stany Zjednoczone, 36606
        • South Alabama Medical Science Foundation
    • Arkansas
      • Little Rock, Arkansas, Stany Zjednoczone, 72202
        • Arkansas Children's Hospital
    • California
      • Orange, California, Stany Zjednoczone, 92868
        • UC Irvine Medical Center
    • Connecticut
      • Farmington, Connecticut, Stany Zjednoczone, 06030
        • UConn-Neag Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • University of Illinois Hospital and Health Sciences System (UI Health)
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • University of Illinois at Chicago (UIC) Clinical Research Center
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Dana-Farber Cancer Institute IDS Pharmacy
      • Boston, Massachusetts, Stany Zjednoczone, 02115
        • Brigham And Woman's Hospital
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48109
        • University of Michigan Hospitals - Michigan Medicine
    • New York
      • The Bronx, New York, Stany Zjednoczone, 10461
        • Jacobi Medical Center
    • North Carolina
      • Durham, North Carolina, Stany Zjednoczone, 27705
        • Duke University Medical Center
      • Durham, North Carolina, Stany Zjednoczone, 27710
        • DUMC Investigational Drug Services Pharmacy
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • McGovern Medical School at UTHealth
      • Houston, Texas, Stany Zjednoczone, 77030
        • UT Physicians Comprehensive Sickle Cell Center Houston
      • Houston, Texas, Stany Zjednoczone, 77030
        • UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
      • Dar es Salaam, Tanzania, 11101
        • National Institute for Medical Research (NIMR)
      • Adana, Turcja (Türkiye), 01130
        • Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
      • Adana, Turcja (Türkiye), 01250
        • Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
      • Ankara, Turcja (Türkiye), 06430
        • Hacettepe University Ihsan Dogramaci Children Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

12 lat i starsze (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

Participants who meet all the following criteria will be eligible for study enrollment:

  1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.

  2. Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.

  3. Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.

  4. If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.

  5. Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:

  1. Female participant who is breastfeeding or pregnant.
  2. Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
  3. Participant withdrew consent from the originating inclacumab clinical study.
  4. Participant was lost to follow-up from the originating inclacumab clinical study.
  5. Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Inclacumab 30 mg/kg

Inclacumab 30 mg/kg administered intravenously (IV)

Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Annualized Rate of Vaso-occlusive Crises (VOCs)
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Number of Inpatient Hospitalization Days for a VOC
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of SCD-related Urgent Care Visits
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Ramy czasowe: From first dose of study treatment (Day 1) up to Week 48

The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

From first dose of study treatment (Day 1) up to Week 48
Annualized Rate of Complicated VOCs
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Red Blood Cell (RBC) Transfusions
Ramy czasowe: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

29 marca 2022

Zakończenie podstawowe (Rzeczywisty)

7 listopada 2025

Ukończenie studiów (Rzeczywisty)

7 listopada 2025

Daty rejestracji na studia

Pierwszy przesłany

29 marca 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

21 kwietnia 2022

Pierwszy wysłany (Rzeczywisty)

27 kwietnia 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

29 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • GBT2104-133
  • 2020-005289-32 (Numer EudraCT)
  • C5361003 (Inny identyfikator: Alias Study Number)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .